A multimodal AI platform integrates models, data, and processing components across biological and chemical modalities to support drug discovery from target identification through clinical candidate selection. It connects protein sequences and structures, molecular graphs, cellular images, omics measurements, clinical records, and scientific text rather than treating each data type in isolation. section 13.1.2 section 13.1
A platform is distinguished by four capabilities:
- Processes diverse biological and chemical data types, sometimes through shared representations and sometimes by passing outputs between specialized models. section 13.1.2
- Spans a discovery workflow that identifies and prioritizes targets, generates and scores molecules, evaluates binding and properties, and selects experimental candidates. section 13.0 section 13.1
- Combines predictive models with generative models, allowing predictions to guide molecule design and design systems to propose testable candidates. section 13.1.2
- Uses experimental results in closed-loop learning, while human experts oversee critical decisions and balance computational predictions against biological validation. section 13.0 section 13.5
BioNeMo as a platform architecture
NVIDIA’s BioNeMo connects protein foundation models such as ESM-2 and AlphaFold2, small-molecule models such as MegaMolBART and MolMIM, and cellular models such as Phenom and Geneformer through containerized microservices. This architecture supports workflows from target identification through lead optimization. The integration may be orchestration rather than genuine data fusion: several single-modality models pass outputs through a pipeline, while shared learned representations remain rarer. section 13.5 section 13.1.2
These platforms accelerate parts of discovery but do not eliminate experimental or clinical constraints. Data quality, interpretability, biological complexity, and clinical timelines remain limiting factors; practical systems therefore augment rather than replace human expertise. section 13.5 section 13.0
